Rocket Pharmaceuticals Announces Pricing of Public Offering of Common Stock
October 03 2022 - 11:21PM
Business Wire
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading
late-stage biotechnology company advancing an integrated and
sustainable pipeline of investigational genetic therapies for rare
childhood disorders with high unmet need, announced today the
pricing of an underwritten public offering of 6,800,000 shares of
its common stock at a public offering price of $14.75 per share.
The gross proceeds to Rocket from the offering, before deducting
underwriting discounts and commissions and offering expenses, are
expected to be $100.3 million. All shares in the offering are to be
sold by Rocket. In addition, Rocket has granted the underwriters a
30-day option to purchase up to an additional 1,020,000 shares of
its common stock. The offering is expected to close on or about
October 6, 2022, subject to customary closing conditions.
Morgan Stanley, J.P. Morgan and SVB Securities are acting as
joint book-running managers, and BTIG is acting as lead manager for
the offering.
The shares are being offered by Rocket pursuant to an effective
shelf registration statement that was previously filed with the
U.S. Securities and Exchange Commission (the “SEC”). The offering
is being made only by means of a written prospectus and prospectus
supplement that form a part of the registration statement. A
preliminary prospectus supplement relating to and describing the
terms of the offering was filed with the SEC and is available on
the SEC’s website at www.sec.gov.
When available, copies of the final prospectus supplement
relating to the offering may be obtained from Morgan Stanley &
Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd
Floor, New York, New York 10014, by telephone at (866) 718-1649, or
by email at prospectus@morganstanley.com; J.P. Morgan Securities
LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue,
Edgewood, New York 11717, by telephone at (866) 803-9204, or by
email at prospectus-eqfi@jpmorganchase.com; or SVB Securities LLC,
Attention: Syndicate Department, 53 State Street, 40th Floor,
Boston, MA 02109, by telephone at (800) 808-7525, ext. 6105, or by
email at syndicate@svbsecurities.com. You may also obtain a copy of
this document free of charge by visiting the SEC’s website at
www.sec.gov.
This press release shall not constitute an offer to sell or a
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities in any state or jurisdiction in
which such offer, solicitation or sale would be unlawful prior to
the registration or qualification under the securities laws of any
such state or jurisdiction.
About Rocket Pharmaceuticals, Inc.
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) is advancing an
integrated and sustainable pipeline of investigational genetic
therapies designed to correct the root cause of complex and rare
childhood disorders. The Company’s platform-agnostic approach
enables it to design the best therapy for each indication, creating
potentially transformative options for patients afflicted with rare
genetic diseases. Rocket's clinical programs using lentiviral
vector (LVV)-based gene therapy are for the treatment of Fanconi
Anemia (FA), a difficult to treat genetic disease that leads to
bone marrow failure and potentially cancer, Leukocyte Adhesion
Deficiency-I (LAD-I), a severe pediatric genetic disorder that
causes recurrent and life-threatening infections which are
frequently fatal, and Pyruvate Kinase Deficiency (PKD), a rare,
monogenic red blood cell disorder resulting in increased red cell
destruction and mild to life-threatening anemia. Rocket’s first
clinical program using adeno-associated virus (AAV)-based gene
therapy is for Danon Disease, a devastating, pediatric heart
failure condition.
Rocket Cautionary Statement Regarding Forward-Looking
Statements
Various statements in this release concerning the timing and
completion of the public offering on the anticipated terms or at
all may constitute forward-looking statements for the purposes of
the safe harbor provisions under the Private Securities Litigation
Reform Act of 1995, as amended, and other federal securities laws.
All such forward-looking statements are based on management’s
current expectations of future events and are subject to a number
of substantial risks and uncertainties, many of which are outside
Rocket’s control, that could cause actual results to differ
materially and adversely from those set forth in or implied by such
forward-looking statements. These risks and uncertainties include
fluctuations in Rocket’s stock price, changes in market conditions
and satisfaction of customary closing conditions related to the
public offering, as well as those risks more fully discussed in the
section entitled "Risk Factors" in the prospectus supplement and
registration statement referenced above, Rocket’s Annual Report on
Form 10-K for the year ended December 31, 2021, filed February 28,
2022 with the SEC and subsequent filings with the SEC including our
Quarterly Reports on Form 10-Q and Current Reports on Form 8-K.
There can be no assurance that Rocket will be able to complete the
public offering on the anticipated terms. Accordingly, you should
not place undue reliance on these forward-looking statements. All
such statements speak only as of the date made, and Rocket
undertakes no obligation to update or revise publicly any
forward-looking statements, whether as a result of new information,
future events or otherwise, unless required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221003006085/en/
Media Kevin Giordano Director, Corporate Communications
kgiordano@rocketpharma.com
Investors Jessie Yeung, M.B.A. Vice President, Investor
Relations and Corporate Finance investors@rocketpharma.com
Rocket Pharmaceuticals (NASDAQ:RCKT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Rocket Pharmaceuticals (NASDAQ:RCKT)
Historical Stock Chart
From Sep 2023 to Sep 2024